Research To Practice | Oncology Videos

Latest Episodes:

HR-Positive and Triple-Negative Metastatic Breast Cancer | Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer Sep 06, 2024

Show notes

Featuring perspectives from Prof Peter Schmid and Dr Sara M Tolaney, including the following topics:

Introduction: Pharmacology and Sequencing of Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) (0:00)
Expanding Role of TROP2-Directed ADCs in mBC Management — Dr Tolaney (21:42)
Other Targets for ADC Therapy in mBC — Prof Schmid (44:59)

CME information and select publications

HR-Positive and Triple-Negative Metastatic Breast Cancer | Professor Peter Schmid, FRCP, MD, PhD Sep 06, 2024

Show notes

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer | Faculty Presentation 2: Other Targets for ADC Therapy in mBC — Professor Peter Schmid, FRCP, MD, PhD

CME information and select publications

HR-Positive and Triple-Negative Metastatic Breast Cancer | Sara M Tolaney, MD, MPH Sep 06, 2024

Show notes

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer | Faculty Presentation 1: Expanding Role of TROP2-Directed Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) Management — Sara M Tolaney, MD, MPH

CME information and select publications

Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Management of Metastatic Urothelial Bladder Cancer (Companion Faculty Lecture) Aug 30, 2024

Show notes

Featuring a slide presentation and related discussion from Dr Michiel van der Heijden, including the following topics:

Efficacy and safety data from the Phase III EV-302/KEYNOTE-A39 trial comparing enfortumab vedotin/pembrolizumab to chemotherapy for patients with previously untreated metastatic urothelial bladder cancer (mUBC) (0:00)
Principal findings from the Phase III CheckMate 901 substudy of nivolumab in combination with chemotherapy and continued as monotherapy compared to chemotherapy alone as first-line treatment for cisplatin-eligible patients with mUBC (14:36)
Key data from the Phase III THOR trial of erdafitinib for patients with relapsed mUBC and susceptible FGFR3 or FGFR2 genetic alterations (22:03)
Long-term findings with sacituzumab govitecan for patients with progressive mUBC; emerging data from the Phase III TROPiCS-04 study (29:43)
Outcomes observed in the cohort of patients with mUBC in the Phase II DESTINY-PanTumor02 trial of trastuzumab deruxtecan (36:19)

CME information and select publications

Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Management of Metastatic Urothelial Bladder Cancer Aug 30, 2024

Show notes

Featuring an interview with Dr Michiel van der Heijden, including the following topics:

Underlying biological mechanisms of the bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition (0:00)
Treatment patterns and survival outcomes for patients admitted to the intensive care unit due to immune-related adverse events (3:15)
Activity of anti-PD1/PD-L1 and anti-CTLA4 combinations for patients with bladder cancer; role of circulating and urinary tumor DNA in urothelial carcinoma (6:40)
Case: A 61-year-old woman with metastatic urothelial bladder cancer (mUBC) treated with first-line enfortumab vedotin and pembrolizumab (19:34)
Case: A 63-year-old man with extensive mUBC whose disease progresses on avelumab maintenance receives enfortumab vedotin (25:54)

CME information and select publications

Breast Cancer | Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Aug 29, 2024

Show notes

Featuring a slide presentation and related discussion from Dr Priyanka Sharma, including the following topics:

Biomarker Assays in the Identification and Prognostication of Patients with Breast Cancer (0:00)
Utility of Circulating Tumor DNA in the Prognostication of Localized Breast Cancer (24:28)
Treatment of HR-Positive, HER2-Negative Advanced Breast Cancer with a PI3K Mutation (29:46)
Utility of Subsequent CDK4/6 Inhibitor After Disease Progression on Initial Therapy (34:57)
Treatment of HER2-Low or HER2-Ultralow Metastatic Breast Cancer (40:59)
Updated Data and Novel Strategies Involving Trastuzumab Deruxtecan for the Treatment of Advanced Breast Cancer (49:42)
Oral Selective Estrogen Receptor Degraders for the Treatment of ER-Positive, HER2-Positive Breast Cancer (51:55)
Novel Strategies Involving Antibody-Drug Conjugates and Immunotherapy for Triple-Negative Breast Cancer (58:12)

CME information and select publications

Metastatic Breast Cancer | Oncology Today with Dr Neil Love: An interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast Cancer Aug 23, 2024

Show notes

Featuring an interview with Prof Giuseppe Curigliano, including the following topics:

Counseling patients with newly diagnosed metastatic breast cancer (mBC); role of patient-reported outcomes and advocacy (0:00)
Individualized selection of up-front therapy for patients with HR-positive, HER2-negative mBC (6:02)
Selection and sequencing of treatment for patients with HR-positive, HER2-negative disease who experience progression on CDK4/6 inhibition (9:40)
Current and future role of HER2-targeted therapy for HER2-low and HER2-ultralow mBC (19:46)
Selection and sequencing of therapy for patients with metastatic triple-negative breast cancer (29:53)
Emerging innovative interventions for the treatment of mBC (37:17)

CME information and select publications

Ovarian and Endometrial Cancer | Oncology Today with Dr Neil Love: An interview with Angeles Alvarez Secord, MD, MHSc — Management of Ovarian and Endometrial Cancer Aug 22, 2024

Show notes

Featuring an interview with Dr Angeles Alvarez Secord, including the following topics:

Front-line management of ovarian cancer (0:00)
Management of relapsed/refractory ovarian cancer (20:06)
Management of microsatellite instability-high/mismatch repair-deficient endometrial cancer (23:20)
Management of microsatellite stable/mismatch repair-proficient endometrial cancer (33:13)
Targeted therapy for gynecologic cancers (44:15)

CME information and select publications

Non-Small Cell Lung Cancer | Professor Solange Peters, MD, PhD Aug 21, 2024

Show notes

Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 1: Significance of Biomarker Testing in Localized Non-Small Cell Lung Cancer (NSCLC) and Historical Management Paradigm for ALK-Positive Disease — Professor Solange Peters, MD, PhD

CME information and select publications

Non-Small Cell Lung Cancer | Professor Ben Solomon, MBBS, PhD Aug 21, 2024

Show notes

Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 2: Emerging Role and Practical Application of ALK-Targeted Therapy in Localized NSCLC — Professor Ben Solomon, MBBS, PhD

CME information and select publications